MARKET

AMPE

AMPE

AMPIO PHARMA
AMEX

Real-time Quotes | Nasdaq Last Sale

1.470
-0.010
-0.68%
After Hours: 1.490 +0.02 +1.36% 19:33 03/08 EST
OPEN
1.470
PREV CLOSE
1.480
HIGH
1.520
LOW
1.430
VOLUME
1.14M
TURNOVER
--
52 WEEK HIGH
2.980
52 WEEK LOW
0.3100
MARKET CAP
287.57M
P/E (TTM)
-19.7315
1D
5D
1M
3M
1Y
5Y
Five Prime Therapeutics leads healthcare gainers; BioVie, Schrodinger maong major losers
Gainers: Five Prime Therapeutics (FPRX) +78%, Ampio Pharmaceuticals (AMPE) +10%, Soligenix (SNGX) +7%.Losers: BioVie (BIVI) -29%, Schrodinger (SDGR) -25%, KemPharm (KMPH) -19%, Anchiano Therapeutics (ANCN) -15%, AbCellera Biologics (ABCL) -12%.
Seekingalpha · 4d ago
Best Penny Stocks To Watch Right Now As Markets Attempt To Rebound
Mar 04, 2021 (Penny Stocks via COMTEX) -- What Does 2021 Have in Store For These 3 Penny Stocks to Watch? You can't argue with the attraction to penny...
Penny Stocks · 4d ago
The Daily Biotech Pulse: FDA Nod For Pfizer, Kiniksa Rises On Commercialization Pact With Regeneron, Bio-Techne To Buy Diagnostic Company
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs March 3)
Benzinga · 4d ago
DJ Ampio Pharmaceuticals' CEO Mike Macaluso on Q4 2020 Results -- Earnings Call Transcript >AMPE
Dow Jones · 4d ago
BRIEF-Ampio Pharmaceuticals Reports Q4 2020 Financial Results
reuters.com · 5d ago
8-K: Ampio Pharmaceuticals, Inc.
(EDGAR Online via COMTEX) -- 0001411906false00014119062020-12-292020-12-29 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K...
Edgar Online - (EDK = 8-Ks/S1/S-4) · 5d ago
10-K: AMPIO PHARMACEUTICALS, INC.
(EDGAR Online via COMTEX) -- Item 7.Management's Discussion and Analysis of Financial Condition and Results of Operations. You should read the following...
Edgar Online - (EDG = 10Q, 10K) · 5d ago
Ampio Pharmaceuticals EPS in-line
Ampio Pharmaceuticals (AMPE): FY GAAP EPS of -$0.09 in-line.Cash and cash equivalents totaled $17.3 million at December 31, 2020, compared to $6.5 million at December 31, 2019.Based on its current
Seekingalpha · 5d ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of AMPE. Analyze the recent business situations of AMPIO PHARMA through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average AMPE stock price target is 4.500 with a high estimate of 5.00 and a low estimate of 4.000.
EPS
Institutional Holdings
Institutions: 82
Institutional Holdings: 20.94M
% Owned: 10.71%
Shares Outstanding: 195.63M
TypeInstitutionsShares
Increased
13
1.36M
New
15
8.35M
Decreased
18
7.05M
Sold Out
15
1.46M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.02%
Pharmaceuticals & Medical Research
-0.50%
Key Executives
Chairman/Chief Executive Officer/Director
Michael Macaluso
Chief Financial Officer/Treasurer/Secretary
Daniel Stokely
Chief Operating Officer
Holli Cherevka
Director
David Bar-Or
Independent Director
Philip Coelho
Independent Director
Richard Giles
Independent Director
David Stevens
No Data
About AMPE
Ampio Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused primarily on the development of therapies to treat prevalent inflammatory conditions for which there are limited treatment options. The Company's two lead product candidates in development are Ampion for osteoarthritis of the knee and Optina for diabetic macular edema. Ampion is a sub 5000 molecular weight fraction of commercial human serum albumin (HSA). Optina is a low-dose formulation of danazol. The Ampio segment consists of its biopharmaceuticals compounds and the clinical trials associated with them. The Company is primarily developing compounds that decrease inflammation by inhibiting specific pro-inflammatory compounds by affecting specific pathways at the protein expression and at the transcription level; activating specific phosphatase or depleting available phosphate needed for the inflammation process, and decreasing vascular permeability.

Webull offers kinds of Ampio Pharmaceuticals Inc stock information, including AMEX:AMPE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AMPE stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading AMPE stock methods without spending real money on the virtual paper trading platform.